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Abstract
Aim Obtain initial estimates of the change in brachial artery endothelial function and maximal oxygen uptake (VO2peak)
with 8 weeks of low-frequency electrical muscle stimulation (LF-EMS) or sham in patients with advanced chronic
heart failure.
Methods and results Using a double blind, randomized design, 35 patients with chronic heart failure (New York Heart
Association class III–IV) were assigned to 8 weeks (5 × 60 min per week) of either LF-EMS (4 Hz, continuous) or sham (skin
level stimulation only) of the quadriceps and hamstrings muscles. Four of the ﬁve sessions were at home and one under
supervision. Ultrasound images of resting brachial artery diameter and post 5 min occlusion to determine ﬂow-mediated
dilation (FMD), a marker of vascular function and peak oxygen uptake (VO2peak) during cardiopulmonary exercise test, were
measured before and after LF-EMS (n = 20) and sham (n = 15) interventions. FMD improved by 2.56% (95% conﬁdence inter-
val: 0.69 to 3.80) with LF-EMS compared with sham (P = 0.07). There were no notable changes in VO2peak.
Conclusions Improvements in FMD with LF-EMS may have a clinically meaningful effect as higher FMD is associated with
better prognosis. This is a preliminary ﬁnding, and a larger trial is warranted.
Keywords Advanced heart failure; Cardiac rehabilitation; Endothelial function electrical muscle stimulation; Neuromuscular electri-
cal stimulation; Flow-mediated dilation
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Introduction
New York Heart Association (NYHA) class III/IV chronic
heart failure (CHF) patients are unable to perform simple
activities of daily living.1 Low ﬁtness2 and endothelial dys-
function3 are predictors of mortality in CHF and are useful
targets for treatment. Low-frequency electrical muscle stim-
ulation (LF-EMS) has been explored as a potential therapy
in patients with mild CHF with positive outcomes.4–6 Im-
provements in exercise capacity and endothelial function
with LF-EMS in patients with CHF NYHA class III/IV could
reduce the incidence of all-cause mortality7 and improve
overall quality of life. We have reported previously that a
randomized control trial is feasible in this patient group,
but minimal improvements in quality of life and functional
capacity were evident.8 Here, we aimed to obtain initial
estimates of the change in brachial artery endothelial func-
tion and maximal oxygen uptake (VO2peak) with LF-EMS in a
subset of patients with CHF class III/IV from our larger fea-
sibility trial.8 We hypothesized that 8 weeks of LF-EMS
would enhance endothelial function and cardiorespiratory
ﬁtness.
Methods
Research design
Fifty-six participants with stable CHF NYHA functional
class III–IV symptoms (ejection fraction <40% on echocar-
diography, Table 1) were randomized to either LF-EMS
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(n = 28) or ‘sham’ placebo (n = 28) for a period of 8 weeks
in a double blind, parallel group, randomized controlled fea-
sibility trial, which is reported elsewhere.8 A subset of par-
ticipants (LF-EMS n = 20, sham n = 15, Figure 1) from the
original trial were able to tolerate the additional research
measurement (withdrawn, n = 10; unable to tolerate tests,
n = 5; refused tests due to illness, n = 6) and underwent as-
sessment of endothelial function and maximal oxygen up-
take. Participants with implantable cardiac devices, life-
threatening cardiac arrhythmias, neurological disorders, or
previous stroke were excluded. The study received ethical
approval and was conducted in accordance with the Decla-
ration of Helsinki. Informed consent was obtained from all
participants.
Low-frequency electrical muscle
stimulation/sham stimulation
Detailed description of the LF-EMS and sham interventions
is described previously.8 Brieﬂy, the LF-EMS equipment
(Biomedical Research Limited, Galway, Ireland) containing
built-in adhesive gel electrodes was worn on the upper
legs. The LF-EMS group received stimulation at a pulse fre-
quency of 4 Hz (pulse width: 620 μs, maximum current
amplitude: 140 mA). The sham group received a very low
level of stimulation (frequency: 99 Hz, pulse width:
150 μs, maximum current amplitude: 7.3 mA). Participants
used the LF-EMS or sham for 1 h, ﬁve times a week, for
8 weeks. Four of the ﬁve sessions were at home and one
under supervision.
Measurements
Brachial artery endothelium-dependent vasodilation was
assessed using the ﬂow-mediated dilation (FMD) technique
following recommended methods.9 Brieﬂy, the brachial
artery was imaged using high-resolution ultrasound (Tersaon
t3000, Aloka, UK) to detect the change in arterial diameter in
response to a 5 min ischaemic stimulus induced by forearm
cuff inﬂation to 220 mmHg.9 Diameter, ﬂow, and shear stress
were measured prior to and following 5 min of forearm cuff
inﬂation. Analysis was performed using custom-designed
edge-detection and wall-tracking software by a single person
who was blinded to treatment allocation. Allometric scaling
for baseline diameter was performed.10 Maximal cardiopul-
monary exercise testing was performed in accordance with
American Thoracic Society guidelines11 on an upright cycle
ergometer with an exercise respiratory gas analysis system
(Oxycon Pro, Jaeger, Warwick, Warwickshire, UK). All assess-
ments were performed prior to and following LF-EMS
or sham.
Statistical analysis
Given that this is a feasibility study, no a priori sample size
was calculated. The sample size of each group in this current
sub-study provides 47% power to detect a between-group
difference in FMD of 1.0% (equivalent to a 20% decreased
mortality in patients with CHF3) assuming a standard devia-
tion of 1.5% for within group change scores and using a
two-sided independent t-test (G*Power 3.1.5).12 This sample
size was deemed appropriate to enable an estimate of sam-
ple size for a larger trial.
Delta changes (Δ) from pre-intervention were calculated
for each group and entered as the dependent variable in a
linear mixed model (Statistical Package for the Social Sciences,
Version 20: SPSS Inc., Chicago, IL) with pre-intervention data
entered as a covariate. Data are presented in the text as mean
and 95% conﬁdence intervals with exact P values.
Results
Brachial artery FMD improved by 2.56% (95% conﬁ-
dence interval: 0.69 to 3.80) with LF-EMS compared with
sham (Figure 2), which approached statistical signiﬁcance
Table 1 Baseline demographic and clinical characteristics of the
LF-EMS and sham placebo groups
EMS intervention
(n = 20)
Sham
(n = 15)
P
value
Demographics
N, Male 13 (65%) 10 (66.6%) 0.92
Age (years) 68.6 ± 9.4 66.7 ± 6.8 0.59
BMI (kg/m2) 29.5 ± 4.7 27.8 ± 5.4 0.1
Clinical
NT-proBNP (pg/mL) 3052 ± 3398 2132 ± 2012 0.23
Creatinine (μmol/L) 101 ± 47 109 ± 41 0.45
LVEF % 39 ± 11 22 ± 12 0.42
BPsys (mmHg) 116 ± 19 123 ± 14 0.16
BPdia (mmHg) 67 ± 11 70 ± 8 0.23
NYHA III 14 (70%) 11 (73.3%) 0.83
NYHA IV 6 (30%) 4 (26.7%) 0.83
Co-morbidities
Prev MI/PCI/CABG 13 (65%) 8 (53.3%) 0.49
Diabetes 10 (50%) 7 (46.6%) 0.84
COPD 5 (25%) 3 (20%) 0.73
AF 14 (68%) 9 (60%) 0.62
Hypertension 9 (45%) 7 (46.6%) 0.92
CKD 5 (25%) 9 (60%) 0.03
AF, atrial ﬁbrillation; BMI, body mass index; BPdia, diastolic blood
pressure; BPsys, systolic blood pressure; CABG, coronary artery by-
pass graft surgery; CKD, chronic kidney disease; COPD, chronic ob-
structive pulmonary disease; LF-EMS, low-frequency electrical
muscle stimulation; LVEF, left ventricular ejection fraction; NT-
proBNP, N terminal pro B-type natriuretic peptide; NYHA, New York
Heart Association; MI, myocardial infarction; PCI, percutaneous
coronary intervention.
Data presented as mean ± standard deviation or absolute number
and per cent.
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(P = 0.07). Based on this outcome, it was estimated that 86
participants per group would be required to have 80% power
to detect a statistically signiﬁcant (P < 0.05) between-group
differences in FMD.
There was also a trend towards a smaller arterial diameter
(Table 2) with sham vs. LF-EMS (P = 0.08). There were no
notable intervention-mediated changes in peak arterial diam-
eter or shear rate and time to peak. There were negligible
Figure 1 Consort diagram of the study; low-frequency electrical muscle stimulation (LF-EMS) vs. sham placebo in severe heart failure patients.
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changes in VO2peak in both groups following the 8 week
intervention period (Table 2).
Discussion
We provide preliminary evidence towards enhanced endo-
thelial function following LF-EMS compared with sham in
patients with CHF NYHA III/IV. Despite no notable changes
in VO2peak, these data suggest that the impact of LF-EMS on
endothelial function should be explored in a larger trial.
This is the ﬁrst study to assess the impact of LF-EMS on
FMD in patients with advanced CHF. Our data suggest
that a sample size of 86 patients per group would be
required to show statistical improvement in FMD with LF-
EMS. We show preliminary evidence of a clinically relevant
improvement in FMD greater than 1%.3 An improvement of
similar or greater magnitude in FMD with a fully powered,
larger study would be important for this group of high-risk
patients, given that (i) a 1% increase in FMD is associated
with a 20% decreased mortality in CHF patients3,7 and (ii)
this group of patients are physically debilitated and gener-
ally contradicted for exercise-based cardiac rehabilitation.
Therefore, LF-EMS may offer an alternative means to con-
ventional exercise in altering blood ﬂow (shear) stress
patterns against the artery walls to improve vascular func-
tion. A noteworthy observation to support the endothelial
function data was evidence of a decrease in artery size in
the sham intervention. A change in artery size may suggest
that the health of the artery is deteriorating possibly
related to persistent physical inactivity,13 but a positive
impact of LF-EMS on artery size may maintain or augment
endothelial function.
The measurement of VO2peak is challenging in this
population. Many participants were unable to meet the
Figure 2 Mean ﬂow-mediated dilation (FMD) change after 8-week low-
frequency electrical muscle stimulation (LF-EMS) or sham. Error bars
are standard deviations.
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requirements for peak oxygen uptake including respiratory
exchange ratio < 1.10 and test duration <8 min,13 suggest-
ing musculoskeletal issues rather than oxygen uptake
were limiting exercise capacity. Given these issues, together
with the ﬁndings from the 6 min walk test previously re-
ported, measuring VO2peak in any larger study may not be
appropriate.
Participants were deemed eligible for the study based on
the judgement of experienced heart failure clinicians using
available knowledge. This may have led to greater variability
in disease severity/limitation between groups; this potential
confounding can be factored into the randomization proce-
dure of any large trial.
In summary, LF-EMS could be useful in improving FMD in
patients with CHF NYHA III/IV, which could improve mortality
and should be explored in a larger trial.
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